Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC
Eric Jonasch, MD
Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).
Sarcomatoid RCC is a difficult disease in regard to efficacy, says Jonasch. But, with studies stating that PD-L1 expression in RCC is high, the use of checkpoint antibodies could be promising.
Jonasch says that this high expression of PD-L1 supports the hypothesis that, if targeted, checkpoint antibodies could be succesful in treatment of patients with the disease.